Sanofi SA (SNY)
47.98
+0.20
(+0.42%)
USD |
NASDAQ |
Nov 21, 16:00
47.98
0.00 (0.00%)
After-Hours: 20:00
Sanofi Revenue (Quarterly): 15.57B for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 15.57B |
| June 30, 2024 | 12.25B |
| March 31, 2024 | 12.08B |
| December 31, 2023 | 13.14B |
| September 30, 2023 | 13.83B |
| June 30, 2023 | 11.65B |
| March 31, 2023 | 11.67B |
| December 31, 2022 | 11.71B |
| September 30, 2022 | 13.23B |
| June 30, 2022 | 11.44B |
| March 31, 2022 | 11.28B |
| December 31, 2021 | 11.91B |
| September 30, 2021 | 12.77B |
| June 30, 2021 | 10.90B |
| March 31, 2021 | 10.71B |
| June 30, 2020 | 9.293B |
| March 31, 2020 | 10.28B |
| December 31, 2019 | 11.09B |
| September 30, 2019 | 11.03B |
| June 30, 2019 | 10.09B |
| March 31, 2019 | 9.897B |
| December 31, 2018 | 10.64B |
| September 30, 2018 | 11.33B |
| June 30, 2018 | 10.13B |
| March 31, 2018 | 9.983B |
| Date | Value |
|---|---|
| December 31, 2017 | 10.60B |
| September 30, 2017 | 11.04B |
| June 30, 2017 | 9.829B |
| March 31, 2017 | 9.478B |
| December 31, 2016 | 9.887B |
| September 30, 2016 | 10.37B |
| June 30, 2016 | 9.386B |
| March 31, 2016 | 8.746B |
| December 31, 2015 | 7.473B |
| September 30, 2015 | 10.76B |
| June 30, 2015 | 9.683B |
| March 31, 2015 | 9.275B |
| December 31, 2014 | 8.817B |
| September 30, 2014 | 11.75B |
| June 30, 2014 | 11.17B |
| March 31, 2014 | 10.86B |
| December 31, 2013 | 8.889B |
| September 30, 2013 | 11.29B |
| June 30, 2013 | 10.56B |
| March 31, 2013 | 10.77B |
| December 31, 2012 | 11.24B |
| September 30, 2012 | 11.55B |
| June 30, 2012 | 11.71B |
| March 31, 2012 | 11.72B |
| December 31, 2011 | 12.02B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
9.293B
Minimum
Jun 2020
15.57B
Maximum
Sep 2024
11.93B
Average
11.69B
Median
Revenue (Quarterly) Benchmarks
| AstraZeneca PLC | 13.56B |
| GSK PLC | 10.43B |
| Eli Lilly and Co | 11.44B |
| Novavax Inc | 84.51M |
| Regeneron Pharmaceuticals Inc | 3.721B |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 3.096B |
| Total Expenses (Quarterly) | 11.07B |
| EPS Diluted (Quarterly) | 1.237 |
| Enterprise Value | 136.14B |
| Gross Profit Margin (Quarterly) | 71.14% |
| Profit Margin (Quarterly) | 19.88% |
| Earnings Yield | 4.11% |
| Operating Earnings Yield | 9.56% |
| Normalized Earnings Yield | 6.677 |